Acetylon Pharmaceuticals Named a “Fierce 15” Biotech Company for 2013

  Acetylon Pharmaceuticals Named a “Fierce 15” Biotech Company for 2013

Business Wire

BOSTON -- September 24, 2013

Acetylon Pharmaceuticals, the leader in the development of selective histone
deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, today
announced that it has been named by FierceBiotech as one of 2013's Fierce 15
biotechnology companies, designating it as one of the most promising private
firms in the industry.

“Acetylon has emerged from one of the most difficult periods for raising funds
for biotech startups in the history of the industry,” said FierceBiotech
Editor John Carroll. “The hard work of forming the Company with an exceptional
$35 million of support from angel investors has paid off with a marquee deal
with Celgene and exciting progress in clinical trials for its potential oral
drug for multiple myeloma.”

The Fierce 15 celebrates the spirit of being "fierce" – championing innovation
and creativity, even in the face of intense competition. This is
FierceBiotech's eleventh annual Fierce 15 selection.

“We are delighted to be selected as part of this year’s ‘Fierce 15’, an award
that honors our employees, founders, and academic and clinical collaborators
for the tremendous work they have done in realizing the immense therapeutic
potential for next-generation, selective HDAC inhibitors, including our lead
drug candidate ACY-1215 for the treatment of hematological malignancies
including multiple myeloma,” commented Walter C. Ogier, President and Chief
Executive Officer of Acetylon. “It is a testament to their hard work and the
promise of these candidates that we have been able to secure a strategic
collaboration with Celgene that includes an option for future acquisition of

Acetylon is developing a portfolio of oral, selective HDAC inhibitors in
oncology, hematology, immunology and neurologic disease. The Company’s lead
candidate, ACY-1215, is an oral HDAC6 inhibitor currently in two clinical
trials for the treatment of relapsed or refractory multiple myeloma: a Phase
1/2 trial in combination with first-in-class drug Velcade® (bortezomib) and a
Phase 1b trial in combination with best-in-class drug Revlimid®
(lenalidomide), which have reported early evidence of a favorable safety
profile for ACY-1215 as well as extensive clinical responses in patients with
advanced disease. In addition, Acetylon is developing a further highly
selective HDAC6 inhibitor for neurodgenerative diseases, an HDAC1/2 inhibitor
for sickle cell disease and beta-thalassemia, and a yet unnamed project –
spanning a broad range of cancer and non-cancer disease indications.

About Acetylon
Acetylon Pharmaceuticals, Inc., based in Boston, Massachusetts, is a leader in
the development of novel small molecule drugs targeting epigenetic mechanisms
for the enhancement of therapeutic outcomes in cancer and other critical human
diseases. The Company’s epigenetic drug discovery platform has yielded a
proprietary portfolio of optimized, orally-administered Class I and Class II
histone deacetylase (HDAC) selective compounds. Alteration of HDAC regulation
through selective HDAC inhibition is thought to be applicable to a broad range
of diseases including cancer, sickle cell disease and beta-thalassemia, and
autoimmune and neurodegenerative diseases. Acetylon’s lead drug candidate,
ACY-1215, is a selective HDAC6 inhibitor currently in Phase 1b clinical
development for the treatment of multiple myeloma. The Company recently
announced a strategic collaboration agreement with Celgene Corporation, which
includes an exclusive option for the future acquisition of Acetylon by
Celgene. Acetylon’s scientific founders are affiliated with the Harvard
University, the Dana-Farber Cancer Institute, the Massachusetts General
Hospital, and Harvard Medical School.

About FierceBiotech
FierceBiotech is the biotech industry's daily monitor - a free email
newsletter and web resource providing the latest biotech news, articles, and
resources related to clinical trials, drug discovery, FDA approval and
regulation, biotech company deals and more. More than 90,000 top biotech
professionals rely on FierceBiotech for an insider briefing on the day's top
stories. Signing up is free.


Walter C. Ogier, 617-435-2664
President and Chief Executive Officer
MacDougall Biomedical Communications
Michelle Avery, 781-235-3060
Kari Watson, 781-235-3060
Press spacebar to pause and continue. Press esc to stop.